MedTrace Logo

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer

NCT00880360 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-03-27

Study results available
· View outcomes & findings →

Summary

This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.

Conditions

  • Epithelial Ovarian Cancer
  • Extraovarian Peritoneal Cancer
  • Fallopian Tube Carcinoma

Interventions

DRUG

Ontak

Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Tyler Curiel, MD, PhD · The University of Texas Health Science Center at San Antonio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00880360 on ClinicalTrials.gov